Sudan Loganathan
Stock Analyst at Stephens & Co.
(3.50)
# 847
Out of 5,135 analysts
45
Total ratings
52.63%
Success rate
6.36%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Sudan Loganathan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| APGE Apogee Therapeutics | Initiates: Overweight | $95 | $70.27 | +35.19% | 1 | Dec 17, 2025 | |
| KYMR Kymera Therapeutics | Maintains: Overweight | $65 → $110 | $85.11 | +29.24% | 3 | Dec 11, 2025 | |
| CADL Candel Therapeutics | Reiterates: Overweight | $15 | $5.85 | +156.41% | 2 | Dec 8, 2025 | |
| PYXS Pyxis Oncology | Maintains: Overweight | $5 → $8 | $1.37 | +483.94% | 2 | Nov 24, 2025 | |
| IMNM Immunome | Maintains: Overweight | $25 → $33 | $21.99 | +50.07% | 3 | Nov 17, 2025 | |
| ARVN Arvinas | Maintains: Overweight | $14 → $15 | $11.82 | +26.90% | 3 | Nov 10, 2025 | |
| DCTH Delcath Systems | Maintains: Overweight | $25 → $18 | $9.48 | +89.87% | 4 | Nov 5, 2025 | |
| CNTA Centessa Pharmaceuticals | Initiates: Overweight | $35 | $25.04 | +39.78% | 1 | Oct 28, 2025 | |
| CCCC C4 Therapeutics | Reiterates: Overweight | $6 | $1.91 | +214.14% | 3 | Sep 22, 2025 | |
| IDYA IDEAYA Biosciences | Reiterates: Overweight | $45 | $30.92 | +45.54% | 3 | Sep 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $30 | $15.48 | +93.80% | 4 | Jul 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $29 → $60 | $44.47 | +34.92% | 5 | Jun 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $33 | $24.29 | +35.86% | 2 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $6 → $8 | $4.13 | +93.70% | 2 | Feb 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $15 | $5.38 | +178.81% | 2 | Jan 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $5 | $1.04 | +380.77% | 2 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $100 | $26.25 | +280.95% | 2 | May 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $1.67 | +1,097.60% | 1 | May 14, 2024 |
Apogee Therapeutics
Dec 17, 2025
Initiates: Overweight
Price Target: $95
Current: $70.27
Upside: +35.19%
Kymera Therapeutics
Dec 11, 2025
Maintains: Overweight
Price Target: $65 → $110
Current: $85.11
Upside: +29.24%
Candel Therapeutics
Dec 8, 2025
Reiterates: Overweight
Price Target: $15
Current: $5.85
Upside: +156.41%
Pyxis Oncology
Nov 24, 2025
Maintains: Overweight
Price Target: $5 → $8
Current: $1.37
Upside: +483.94%
Immunome
Nov 17, 2025
Maintains: Overweight
Price Target: $25 → $33
Current: $21.99
Upside: +50.07%
Arvinas
Nov 10, 2025
Maintains: Overweight
Price Target: $14 → $15
Current: $11.82
Upside: +26.90%
Delcath Systems
Nov 5, 2025
Maintains: Overweight
Price Target: $25 → $18
Current: $9.48
Upside: +89.87%
Centessa Pharmaceuticals
Oct 28, 2025
Initiates: Overweight
Price Target: $35
Current: $25.04
Upside: +39.78%
C4 Therapeutics
Sep 22, 2025
Reiterates: Overweight
Price Target: $6
Current: $1.91
Upside: +214.14%
IDEAYA Biosciences
Sep 9, 2025
Reiterates: Overweight
Price Target: $45
Current: $30.92
Upside: +45.54%
Jul 10, 2025
Reiterates: Overweight
Price Target: $30
Current: $15.48
Upside: +93.80%
Jun 24, 2025
Upgrades: Overweight
Price Target: $29 → $60
Current: $44.47
Upside: +34.92%
Feb 27, 2025
Reiterates: Overweight
Price Target: $33
Current: $24.29
Upside: +35.86%
Feb 24, 2025
Maintains: Overweight
Price Target: $6 → $8
Current: $4.13
Upside: +93.70%
Jan 22, 2025
Reiterates: Equal-Weight
Price Target: $15
Current: $5.38
Upside: +178.81%
Nov 19, 2024
Reiterates: Overweight
Price Target: $5
Current: $1.04
Upside: +380.77%
May 24, 2024
Reiterates: Overweight
Price Target: $100
Current: $26.25
Upside: +280.95%
May 14, 2024
Initiates: Overweight
Price Target: $20
Current: $1.67
Upside: +1,097.60%